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Abstract 
The purpose of clinical definitions of the metabolic syndrome is frequently misunderstood. While the 
metabolic syndrome as a physiological process describes a clustering of numerous age-related 
metabolic abnormalities that together increase the risk for cardiovascular disease and type 2 
diabetes, clinical definitions include obesity which is thought to be a cause rather than a 
consequence of metabolic disturbance, and several elements that are routinely measured in clinical 
practice, including high blood pressure, high blood glucose and dyslipidaemia. Obesity is frequently a 
central player in the development of the metabolic syndrome and should be considered a key 
component of clinical definitions. Previous clinical definitions have differed in the priority given to 
obesity. Perhaps more importantly than its role in a clinical definition, however, is obesity in 
isolation before the hallmarks of metabolic dysfunction that typify the syndrome have developed. 
This should be treated seriously as an opportunity to prevent the consequences of the global 
diabetes epidemic now apparent. Clinical definitions were designed to identify a population at high 
lifetime CVD and type 2 diabetes risk, but in the absence of several major risk factors for each 
condition, are not optimal risk prediction devices for either. Despite this, the metabolic syndrome 
has several properties that make it a useful construct, in conjunction with short-term risk prediction 
algorithms and sound clinical judgement, for the identification of those at high lifetime risk of CVD 
and diabetes. A recently published consensus definition provides some much needed clarity about 
what a clinical definition entails. Even this, however, remains a work in progress until more evidence 
becomes available, particularly in the area of ethnicity-specific waist cut-points.  
Introduction 
The term “metabolic syndrome” has developed to describe those individuals at increased risk of type 
2 diabetes and cardiovascular diseases (CVD) due to the metabolic dysfunction commonly seen in 
individuals with insulin resistance. Clinical definitions of the metabolic syndrome have been 
developed in the last two decades, with a primary purpose being to assist in the identification of 
those at increased diabetes and CVD risk in order to put in place preventive measures that can 
reduce this risk.(1-5) As clinical constructs, these do not need to include all of the abnormalities 
associated with the metabolic dysfunction characteristic of the syndrome, and even include central 
obesity which is more often thought to be a cause rather than a consequence of metabolic 
dysfunction. Despite evidence supporting their ability to independently predict both type 2 diabetes 
and CVD, the various clinical definitions of the metabolic syndrome have been the subject of 
considerable controversy.(6-13) Commentators have questioned their validity and utility for use in 
clinical practice and as a public health tool because of the existence of multiple competing 
definitions and because other tools appear to be more useful for the prediction of CVD and type 2 
diabetes. With the recent publication of a consensus definition of the metabolic syndrome,(5) it is 
timely to review the evidence for its use in the prediction of CVD and diabetes risk.  
 
Issues relating to clinical definitions for the metabolic 
syndrome 
The recent publication of a consensus statement on the definition of the metabolic syndrome, 
representing the views of six major organisations and societies, will hopefully prove to be a pivotal 
point in the development of the metabolic syndrome as a tool for clinical and public health use.(5) A 
major criticism levelled at the metabolic syndrome has been that multiple competing definitions are 
at best confusing, and at worst represent a syndrome which nobody knows how to define. The 
consensus definition (Table 1) represents a compromise of sorts between the previous International 
Diabetes Federation (IDF)(14) and American Heart Association/National Heart, Lung, and Blood 
Institute definitions(3). Previously, the only difference between these two commonly used 
definitions was the structure (any three of five abnormalities constituting a diagnosis for AHA/NHLBI; 
obesity plus two other abnormalities constituting a diagnosis for IDF), and the cut-points for obesity 
(lower and ethnicity-specific cut-points used in the IDF definition). The new consensus definition 
uses the structure of the American definition, with the IDF ethnicity-specific cut-points for obesity 
incorporated. No compromise was reached on obesity cut-points for Europid populations, however, 
with the recommendation that either the higher or lower waist circumference cut-points used in the 
previous definitions can be used based on the practical requirements of local (national) decision 
making groups. In research studies, results for both sets of cut-points should be reported. It is 
important to acknowledge that the new definition is an interim statement, with an 
acknowledgement that further evidence regarding the risk at waist thresholds in different ethnic 
groups should be taken into account in future iterations. Furthermore, the statement makes the 
point that both the World Health Organization and the American National Heart, Lung, and Blood 
Institute (NHLBI) are both re-considering the definition of the metabolic syndrome.(5) It can only be 
hoped that the present interim consensus statement will influence those organisations to come to 
an agreed definition. 
The stronger link between the metabolic syndrome and type 2 diabetes compared to CVD is related 
to the composition of the clinical definitions. Of the five components of clinical metabolic syndrome 
definitions, all are stronger predictors for diabetes than CVD, with obesity and elevated glucose 
being particularly strong type 2 diabetes risk factors (Figure 1).(15) Impaired fasting glucose (IFG) is 
such a strong risk factor for diabetes that it has been shown to be the equal of the metabolic 
syndrome as a whole for prediction of incident diabetes.(16) The fact that the metabolic syndrome is 
a far stronger predictor of type 2 diabetes than CVD is therefore unsurprising. Important risk factors 
for each of type 2 diabetes and CVD are absent (including smoking, age, family history, physical 
activity levels, LDL cholesterol, diet), meaning that risk prediction devices specific to each condition 
usually perform better than the metabolic syndrome.(16, 17)  
The role of obesity in clinical definitions of the metabolic 
syndrome 
Obesity is frequently cited as being a leading cause of the metabolic syndrome. In a review of the 
metabolic syndrome after menopause, Lobo commented that the increased prevalence of the 
metabolic syndrome among women post-menopause is a result chiefly of weight gain and obesity in 
this group.(18) The major difference between the IDF and AHA/NHLBI metabolic syndrome 
definitions is the priority given to obesity. In the IDF definition, one cannot be diagnosed without 
being obese. Critics of this definition will point out that a proportion of individuals with metabolic 
dysfunction are not obese, and these individuals are therefore excluded from this definition. In 
reality, however, the majority of individuals meeting the criteria for either the IDF or AHA/NHLBI 
definitions will also meet the obesity criteria, whether it is a required component or not. In an 
unpublished observation from the national and population representative Australian AusDiab 
study,(19) less than three percent of those not diagnosed by the IDF criteria would meet the criteria 
if obesity were not a required component. 
Perhaps the most important point regarding the position of obesity in clinical metabolic syndrome 
definitions is that obesity is not simply important as a correlate of disease that is already present, 
but is a warning of the development of future disease. Our own research is in support of this view, 
demonstrating that central obesity (as measured using waist circumference) precedes the 
deterioration of the other components of the metabolic syndrome (dyslipidaemia, hyperglycaemia, 
hypertension and insulin resistance).(20) As a public health tool, obesity in isolation is an important 
target, as recognised by the Japanese government in their recent announcement of laws that require 
the annual measurement of the waistlines of all 40 to 74 year old employees of all Japanese 
companies and local governments (44% of the entire Japanese population).(21) We have previously 
highlighted the importance of recognizing obesity in isolation as a significant risk for future 
metabolic deterioration(22) using the following example: 
“A 30-year-old male has a waist circumference of 130 cm (and a body mass 
index of 35.0 kg ⁄m2) and is therefore markedly obese, but does not (yet) have 
the hypertension, dyslipidaemia or elevated blood glucose characteristic of the 
metabolic syndrome.” 
 
Using available risk calculators, this individual is classified as at low risk of both diabetes and 
coronary heart disease. With an otherwise normal metabolic profile, his risk of developing diabetes 
over the next 7.5 years, calculated using a diabetes-specific risk engine, is less than fiver percent.(23) 
His ten year risk of coronary heart disease is even lower at one percent.(24) The reason for such low 
levels of calculated risk is largely a result of risk prediction models generally providing only short 
term risk prediction (i.e. over the next 5-15 years). His lifetime risk, which is substantial purely 
because of his obesity at such a young age, is not accounted for in such models. Indeed, the ten year 
risk for coronary heart disease using the Framingham risk algorithm remains low even in those 
young men with a substantial risk factor burden. Longer term studies clearly show that the obesity-
related risk of coronary heart disease morbidity and mortality only becomes fully apparent after 
many years of follow-up.(25-27) The fact that the case referred to above does not meet the criteria 
for the metabolic syndrome does not mean that he is at low lifetime risk of adverse outcomes, but 
rather highlights the importance of recognising that obesity is the important risk factor for the 
development of metabolic abnormalities well before they actually develop. The optimal time for 
intervention for such individuals was actually their infancy, childhood and early adulthood when 
behaviour patterns are becoming established, not when they finally develop the hallmarks of the 
metabolic syndrome.  
As a final note on the importance of obesity, it is also worth acknowledging that a proportion of 
obese individuals will remain metabolically healthy despite high levels of body fat through their 
genetic resilience to obesity-related metabolic complications. Likewise, a small proportion of those 
who develop metabolic dysfunction will do so despite remaining non-obese. 
The Metabolic syndrome as a tool for prediction of incident 
type 2 diabetes and CVD 
Numerous studies have quantified the risk for type 2 diabetes and CVD associated with clinical 
definitions of the metabolic syndrome. A recent meta-analysis of the studies examining risk for 
incident diabetes showed that for those definitions published prior to the recent consensus 
statement, the metabolic syndrome conferred a relative risk of between 3.1 and 5.1.(28) A similar 
meta-analysis focused on CVD showed that the metabolic syndrome is a comparatively poor 
predictor of CVD (estimated relative risk of 1.7 to 1.9) as well as all-cause mortality (estimated 
relative risk of 1.2 to 1.4).(29) While clearly a better predictor of diabetes than CVD, it is important 
to note that diabetes itself is a major risk factor for future CVD, with diabetes conferring a relative 
risk of between 2 and 4 for CVD (higher in women than men)(30) and some estimates suggesting 
that half to two thirds of deaths in people with diabetes are due to CVD.(30) Diabetes is considered a 
risk equivalent to previous coronary heart disease for development of future CVD events.(31) Most 
studies examining the risk between the metabolic syndrome and CVD are relatively short-term, and 
do not therefore capture the increase in CVD risk possible through first developing type 2 diabetes. 
An analysis of total and CVD mortality over a 33 year follow-up showed the metabolic syndrome to 
be a risk factor independent of other established risk factors, including smoking, hypertension, 
diabetes and cholesterol. This result may indicate the longer-term prognostic value of the metabolic 
syndrome for CVD over and above that achieved by short-term global risk calculators.(32) The 
heterogeneity of the metabolic syndrome is a problem when assessing risk for future diabetes and 
CVD. The level of risk has been shown to differ depending on what combination of abnormalities are 
present,(33) meaning that depending on the combination of abnormalities present, the diabetes or 
CVD risk may be higher or lower than the estimates for the syndrome considered as a whole. 
Much of the diabetes risk associated with the metabolic syndrome is due to the presence of 
“prediabetic” fasting glucose in the definition. It is not at all surprising that a large proportion of 
those with already elevated glucose levels go on to develop frank diabetes. Research using the 
Australian AusDiab study and a comparable national study from Mauritius (among an ethnically 
South Asian and Creole population) have now shown that in fact simple measurement of fasting or 
2-hour post load glucose may be at least as predictive of the development of diabetes compared 
with the metabolic syndrome as a whole.(16, 17) Similarly, the diabetes predicting model developed 
in the San Antonio Heart study was superior to dichotomous definitions of the metabolic 
syndrome.(16) A third predictive tool tested in the Australian study was the non-invasive FINnish 
Diabetes RIsk Score (FINDRISC), which incorporates self report of age, body mass index and waist 
circumference, physical activity, diet, family history of diabetes and previous diagnosis of elevated 
glucose levels (but not in the range for diabetes). The metabolic syndrome was found to be 
somewhat better than this score for identification of those who developed diabetes in this 
population.(16) This research supports a common criticism of the metabolic syndrome, in that it is 
no more useful than its collective component parts. A similar conclusion was reached in a Swedish 
study among a cohort of middle aged men looking at the metabolic syndrome and cardiovascular 
mortality. In this study, men were tested at ages 50 and 70 years, and followed up for a median of 
29 and 9 years respectively for cardiovascular mortality. Unadjusted, the metabolic syndrome was a 
significant predictor (stronger at age 50 than age 70), however after adjustment for its component 
parts, this significant association was not seen. In contrast, at age 50, four of the five components of 
the metabolic syndrome remained significantly associated with CVD death even after adjustment for 
each other and the metabolic syndrome as a whole. The fifth component, elevated glucose, was only 
a significant predictor at age 70. These results remained consistent after the exclusion of those with 
pre-existing disease at baseline. The authors surmise that “if the results of the present study are 
confirmed in other samples, the metabolic syndrome might be viewed as a clinically handy summary 
measure of nontraditional risk factors rather than as a strong biological entity.”(34)   
The scientific justification of the concept of the metabolic syndrome is that the clustering of 
abnormalities that it constitutes are actually representative of an underlying and separate metabolic 
disturbance (which may be insulin resistance, or could be related more to inflammation or obesity, 
although these hypotheses are not mutually exclusive).(35) It might therefore be assumed that 
clinical definitions of the metabolic syndrome would identify an additional element of cardio-
metabolic risk.(36) This assumption, however, does not fully take into account the purpose of clinical 
definitions of the metabolic syndrome. In fact, they were developed as summary measures that 
would identify a group of people who exhibit the hallmarks of metabolic dysfunction and would 
therefore be at increased risk of both type 2 diabetes and CVD, therefore being useful in the clinical 
setting and as a public health tool.(22) The construction of the metabolic syndrome as a 
dichotomous (yes/no) diagnosis, with dichotomies also present for each of the constituent 
abnormalities, and with an absence of numerous type 2 diabetes and CVD risk factors has resulted in 
a fairly blunt, but still clinically useful definition. It is perhaps not surprising then, or even 
problematic, that such a definition does not fully capture the underlying risk factor responsible, and 
represent an independent risk factor.  
As has previously been published, even though the metabolic syndrome was not designed as a tool 
that optimally predicts absolute risk of future CVD and type 2 diabetes, it certainly does identify a 
population at high future risk of both conditions.(22) If nothing else, the ability to relay to a patient 
the interconnected nature of the multiple abnormalities for which they are being treated (and the 
fact that they can all be improved through lifestyle modification) is a useful feature of a clinical 
metabolic syndrome definition. Used in conjunction with the knowledge that it does not recognize 
some risk factors for type 2 diabetes, and with the use of other appropriate short-term risk 
prediction tools, the metabolic syndrome can certainly perform a useful clinical role. 
Conclusions 
The increase in the prevalence of obesity and the metabolic syndrome since the middle of the 
twentieth century is threatening to prevent achievement of the millennium development goals, with 
the increasing global burden of non-communicable diseases being described as the new agenda for 
global public health.(37) Clinical definitions of the metabolic syndrome, while therefore obviously 
important, have frequently been criticized for being sub-optimal in their ability to predict the 
development of type 2 diabetes and CVD. While clearly identifying a group at increased risk of both 
conditions, evidence suggests that the metabolic syndrome is not independent of its component 
parts, and is not the most effective predictor of short-term risk due to the absence of several 
disease-specific risk factors. The mission statement for clinical definitions of metabolic syndrome, 
however, is to identify those at high lifetime risk of both type 2 diabetes and CVD, and evidence is 
accumulating that it is highly useful for that purpose. The metabolic syndrome differentiates itself 
from short-term risk calculators in that it does not include age, and can therefore indicate high risk 
at any age. Furthermore, its dichotomous nature means it is useful for diagnostic purposes, for 
calculating the prevalence in a population, and for helping patients understand that the multiple 
abnormalities they present with are all related (and all potentially modifiable through lifestyle 
modification). Obesity is central to the concept of the metabolic syndrome, but is considered a cause 
rather than a symptom. Because obesity is important years before the development of the other 
abnormalities that together constitute the syndrome, it is important to recognise that obesity in 
isolation is the important risk factor for future metabolic deterioration. Clinical and public health 
interventions may be more effective in those who have not yet developed the full metabolic 
syndrome but are obese. The latest definition of the metabolic syndrome is a useful step forward 
toward a single, unified definition with a clear mission statement. While not the optimal device for 
diabetes and CVD risk prediction (none exist), the metabolic syndrome, used in conjunction with 
other shorter-term risk prediction algorithms and sound clinical judgement, should be considered a 
useful tool for the prevention of the serious consequences of diabetes and CVD.  Further refinement 
of the clinical definition (and in particular the obesity cut points it contains), using new evidence 
relating to the risk of CVD and type 2 diabetes as it becomes available, will further strengthen the 
concept and utility of the metabolic syndrome.   
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Table 1. Consensus criteria for clinical diagnosis of the metabolic syndrome.(5) 
Measure Categorical Cut Points 
Elevated waist circumference* Population and country-specific definitions* 
Elevated triglycerides (drug treatment for 
elevated triglycerides is an alternate indicator†) 
≥150 mg/dL (1.7 mmol/L) 
Reduced HDL-C (drug treatment for reduced 
HDL-C is an alternate indicator†) 
<40mg.dL (1.0 mmol/L) in males; 
<50 mg/dL (1.3 mmol/L) in females 
Elevated blood pressure (antihypertensive drug 
treatment in a patient with a history of 
hypertension is an alternate indicator) 
Systolic ≥130 and/or diastolic ≥85 mm Hg 
Elevated fasting glucose‡ (drug treatment of 
elevated glucose is an alternate indicator) 
≥100 mg/dL 
HDL-C indicates high-density lipoprotein cholesterol 
*It is recommended that the IDF cut points be used for non-Europeans and either the IDF of AHA/NHLBI but points used for 
people of European origin until more data are available. (For a list of current recommended waist circumference in 
different ethnic groups, see the consensus statement).(5) 
†The most commonly used drugs for elevated triglycerides and reduced HDL-C are fibrates and nicotinic acid. A patient 
taking 1 of these drugs can be presumed to have high triglycerides and low HDL-C. High dose *-3 fatty acids presumes high 
triglycerides. 
‡Most patients with type 2 diabetes mellitus will have the metabolic syndrome by the proposed criteria. 
 
 
Table 2. The positives and negatives of the metabolic syndrome for prediction of future diabetes and 
CVD. 
Negative aspects of the Metabolic Syndrome for prediction of future diabetes and CVD - Several major risk factors for both diabetes and CVD not included in clinical definitions - Different combinations of abnormalities confer different levels of risk - Measurement of glucose alone may be just as good for diabetes risk prediction - The metabolic syndrome may not be a risk factor that is independent of its component parts - Cut-points for obesity in different ethnic groups not based on sound evidence 
Positive aspects of the Metabolic Syndrome for prediction of future diabetes and CVD - Does not include age, so can identify young people as being at high risk, unlike most risk 
equations - Is dichotomous, so allows measurement of changes in the proportion of a population at high 
risk over time - Is useful for explaining to patients why the component conditions are all linked - Is simpler to calculate than a complex risk equation - Is related to a 3 to 5 fold greater risk of diabetes, and a 1.7 to 1.9 fold greater risk of CVD - May be particularly useful for long-term risk prediction 
 
Figure 1. Relative risk for CVD and diabetes associated with the metabolic syndrome. (Adapted from 
Wannamethee, 2008)(15) 
 
Figure 2. Relative risk for CHD and diabetes associated with components of the metabolic syndrome. 
(Adapted from Wannamethee, 2008)(15)  
 
